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The Eliminate Yellow fever Epidemics (EYE) strategy was launched in 2017 in response to
the resurgence of yellow fever in Africa and the Americas. The strategy relies on several
vaccination activities, including preventive mass vaccination campaigns (PMVCs). How-
ever, to what extent PMVCs are associated with a decreased risk of outbreak has not yet
been quantified.
Methods and findings
We used the self-controlled case series (SCCS) method to assess the association between
the occurrence of yellow fever outbreaks and the implementation of PMVCs at the province
level in the African endemic region. As all time-invariant confounders are implicitly controlled
for in the SCCS method, this method is an alternative to classical cohort or case–control
study designs when the risk of residual confounding is high, in particular confounding by
indication. The locations and dates of outbreaks were identified from international epidemio-
logical records, and information on PMVCs was provided by coordinators of vaccination
activities and international funders. The study sample consisted of provinces that were both
affected by an outbreak and targeted for a PMVC between 2005 and 2018. We compared
the incidence of outbreaks before and after the implementation of a PMVC. The sensitivity
of our estimates to a range of assumptions was explored, and the results of the SCCS
method were compared to those obtained through a retrospective cohort study design. We
further derived the number of yellow fever outbreaks that have been prevented by PMVCs.
The study sample consisted of 33 provinces from 11 African countries. Among these, the
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first outbreak occurred during the pre-PMVC period in 26 (79%) provinces, and during the
post-PMVC period in 7 (21%) provinces. At the province level, the post-PMVC period was
associated with an 86% reduction (95% CI 66% to 94%, p < 0.001) in the risk of outbreak as
compared to the pre-PMVC period. This negative association between exposure to PMVCs
and outbreak was robustly observed across a range of sensitivity analyses, especially when
using quantitative estimates of vaccination coverage as an alternative exposure measure,
or when varying the observation period. In contrast, the results of the cohort-style analyses
were highly sensitive to the choice of covariates included in the model. Based on the SCCS
results, we estimated that PMVCs were associated with a 34% (95% CI 22% to 45%) reduc-
tion in the number of outbreaks in Africa from 2005 to 2018. A limitation of our study is the
fact that it does not account for potential time-varying confounders, such as changing envi-
ronmental drivers of yellow fever and possibly improved disease surveillance.
Conclusions
In this study, we provide new empirical evidence of the high preventive impact of PMVCs on
yellow fever outbreaks. This study illustrates that the SCCS method can be advantageously
applied at the population level in order to evaluate a public health intervention.
Author summary
Why was this study done?
• Yellow fever is a mosquito-borne, vaccine-preventable disease that may cause large
urban outbreaks, especially in tropical African regions.
• Since 2006, preventive mass vaccination campaigns (PMVCs) have been implemented
in many African provinces. These are large-scale vaccination campaigns targeting all or
most age groups in a specific area.
• The preventive impact PMVCs may have on the risk of yellow fever outbreak has not
been quantified yet.
What did the researchers do and find?
• We used the self-controlled case series (SCCS) method to assess the association between
PMVCs and outbreak risk at the province level in 34 African countries between 2005
and 2018.
• We compared pre- and post-PMVC periods within each province individually, thus
implicitly controlling for all possible confounders that do not vary in time, especially the
fact that provinces indicated for PMVCs are generally those considered at highest base-
line risk of yellow fever (confounding by indication).
• At the province level, we estimated that implementation of PMVCs was associated with
an 86% reduction (95% CI 66% to 94%) in the risk of yellow fever outbreak.
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• A complete cohort analysis provided less reliable results than the SCCS method, likely
because of confounding by indication that was not entirely controlled for by adjusting
for known drivers of yellow fever.
• We further estimated that all PMVCs conducted between 2006 and 2018 in Africa may
have reduced the total number of yellow fever outbreaks by 34% (95% CI 22% to 45%).
What do these findings mean?
• These results provide new empirical evidence of the high preventive impact of PMVCs
on yellow fever outbreaks.
• These results may encourage rapid rescheduling of yellow fever PMVCs that have been
postponed due to the COVID-19 pandemic.
• The SCCS design may be advantageously applied at the population level to assess the
impact of public health interventions.
Introduction
Recent years have seen the resurgence of yellow fever outbreaks in Africa and Latin America
[1]. Regarding Africa specifically, 5 alerts have been issued for the first semester of 2020 alone
(Uganda, South Sudan, Ethiopia, Togo, and Gabon) [2]. As a response to the large-scale
Angola 2015–2016 outbreak, the World Health Organization (WHO) launched the Eliminate
Yellow fever Epidemics (EYE) initiative in 2017 [3]. This strategy aims at preventing sporadic
cases sparking urban outbreaks and potentially triggering international spread. It relies on var-
ious vaccination activities, including preventive mass vaccination campaigns (PMVCs) that
target all or most age groups in a specific area. Evaluating the health impact of such campaigns
is key for informing further PMVCs within or beyond the EYE strategy, to ensure population
acceptance and adherence to vaccination campaigns, and to sustain domestic and interna-
tional efforts for vaccination activities.
Previous attempts have been made to estimate the impact of vaccination activities, includ-
ing PMVCs [4–6]. These attempts mostly relied on mathematical models to estimate PMVC
impact in terms of deaths or cases prevented over the long term. However, few studies aimed
at quantifying the effect of vaccination campaigns on the risk of outbreak. Regardless of the
number of cases they may generate, outbreaks can possibly lead to healthcare, economic, and
social destabilizations of entire regions. As an example, the West African 2013–2016 Ebola out-
break strained health systems. This caused excess deaths due to neglected malaria control
[7,8].
When assessed at the population level, the association between vaccination activities and
risk of outbreak can be approached within a classical epidemiological perspective. In the same
way that individual participants are followed up in cohort studies, populations (e.g., popula-
tions living in well-defined geographical areas) can be followed over time while tracking both
population-level exposure (implementation of vaccination activities) and events (outbreaks).
In such observational studies, a risk of confounding arises when both exposure and event
share a same cause. This risk is high when measuring the association between PMVCs and
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yellow fever outbreaks because PMVCs usually target areas that are assessed as being at partic-
ularly high risk by public health officials, due to disease circulation in the past or based on
expert view or risk assessment [9]. Such a risk of confounding by indication is usually over-
come in the statistical analysis by conditioning on (generally by adjusting for) the shared
common cause; in this case the baseline risk of yellow fever in the area. However, the environ-
mental or demographic drivers of yellow fever are not fully understood [10,11], leading to a sit-
uation in which residual confounders may bias the measure of association.
The self-controlled case series (SCCS) method is a case-only epidemiological study design
for which individuals are used as their own control [12]. As all known and unknown time-
invariant confounders are implicitly controlled for, the method is a relevant alternative to clas-
sical cohort or case–control study designs when the risk of residual confounding is high. The
SCCS method has successfully been applied at the individual level, comparing exposure versus
non-exposure periods within individual cases [13]. However, to our knowledge, this method
has never been used for population-level case series to evaluate the health effects of a public
health intervention in specific regions, countries, or other predefined geographical clusters
that may be considered as group-level cases.
Here, we illustrate the use of the SCCS method at the population level by assessing the asso-
ciation between the implementation of PMVCs and the occurrence of yellow fever outbreaks
at the province level in the African endemic region between 2005 and 2018.
Methods
Study hypotheses
Considering the yellow fever vaccine’s high level of efficacy [14], and given the fact that
PMVCs target all or most age groups in targeted areas, we expected to detect a substantial pre-
ventive effect of PMVCs on the risk of outbreak. We also expected to detect this association in
a cohort design, providing confounders in the association between exposure to PMVCs and
outbreaks were adequately controlled for (no model misspecification). A SCCS model would
avoid the risk of residual confounding, at least for time-independent variables, but would
reduce statistical power as compared to a cohort design analysis [15].
Data used
This study relied on datasets that were previously collected and regularly updated for a broader
project aiming at estimating the burden of yellow fever and the impact of vaccine activities
[4,6]. The analytic plan was defined before the start of the analysis. This study did not require
ethical approval.
In 2005, the WHO Regional Office for Africa established a yellow fever surveillance data-
base across 21 countries in West and Central Africa based on reports of suspected yellow fever
cases [4]. The establishment of this database is likely to have influenced the standards of yellow
fever surveillance in these countries. In order to reduce the possible effect of time-varying
surveillance quality, the beginning of the study period was set at this date. We compiled loca-
tions and dates of yellow fever outbreaks reported in Africa between 1 January 2005 and 31
December 2018 from international epidemiological reports, namely the WHO Weekly Epide-
miological Record (WER) and Disease Outbreak News (DONs) [16,17]. As per WHO recom-
mendations, a single, confirmed yellow fever case is sufficient to justify outbreak investigation.
Based on the results of the investigation and on the absence of other suspected cases, an alert
can be classified as an isolated case; such cases were not considered for this study [18]. Loca-
tions were resolved at the first subnational administrative level, hereafter called province, and
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data were recorded for each outbreak with the date of occurrence. Outbreak reports that could
not be located at the province level were excluded.
We compiled data regarding PMVCs conducted as part of the Yellow Fever Initiative since
2006 [19], and additional campaigns conducted under the EYE strategy [1]. Starting dates and
locations of PMVCs were collected, the resulting list of vaccination campaigns was compared
with data from the WHO International Coordinating Group (ICG) on Vaccine Provision, and
discrepancies were resolved. This virtually ensured completeness of information regarding
mass vaccination activities. Note that information on the vaccine strain used for PMVCs was
not widely available; however, the 2 vaccine strains recommended by WHO (17D and 17DD)
do not differ in terms of immunogenicity [14,20]. PMVCs considered here involved full-dose
vaccine only, as fractional-dose vaccination has been approved by WHO only as part of an
emergency response to an outbreak if there is a shortage of full-dose yellow fever vaccine [21].
Estimates of population-level vaccine-induced protection against yellow fever were
obtained from Hamlet et al. [22]. These estimates were obtained by compiling regularly
updated vaccination data from different sources (routine infant vaccination, reactive cam-
paigns, PMVCs) and inputting these into a demographic model.
Main SCCS analysis. For our main analysis, we used the SCCS method to estimate the
incidence rate ratio (IRR) of yellow fever outbreak after versus before the implementation of a
PMVC. We used the province as the unit of analysis, so that the main outcome represents the
risk for a province to be affected by an outbreak. As the dependence between potential out-
break recurrences in the same province could not be excluded, we limited the analyses to the
first outbreak occurrence per province for the main analysis [23]. We used a conditional Pois-
son model with logit link to model the occurrence of outbreaks [15].
Provinces included in the SCCS analysis were those both affected by an outbreak and tar-
geted for a PMVC over a study period from 1 January 2005 to 31 December 2018. We defined
the unexposed period as the pre-PMVC period. Previous research found that a single dose of
yellow fever vaccine provides long-lasting immunity with high efficacy [14,20]. Therefore, and
given the relatively short observation period of the study (14 years), we assumed the exposure
period started at the date of the first PMVC and lasted until the end of the observation period.
This assumption was made regardless of estimated achieved coverage or intra-province geo-
graphic extent of the campaigns. In other words, we assumed the campaigns achieved uniform
high coverage in all age groups across provinces and that this high coverage was maintained
up to the end of the study period. This assumption of persisting high coverage is further justi-
fied by the inclusion of yellow fever vaccine in the Enhanced Programme on Immunization of
most of the countries in the study region [24]. Routine infant vaccination may not rapidly
increase population-level immunity by itself, but is critical for maintaining high levels once
achieved by the means of PMVCs.
Alternative SCCS models and sensitivity analyses. In order to allow for possible varia-
tion in the coverage achieved across PMVCs, we considered estimated population-level vac-
cine coverage as an alternative time-varying, quantitative exposure (considered as categories
with 20% bandwidth: 0%–19%, 20%–39%, 40%–59%, 60%–79%, and 80%–100%).
We also used alternative SCCS models to assess the influence of several assumptions on our
results (Table 1) [12]. We conducted an SCCS analysis considering all outbreaks, instead of the
first one only, in order to evaluate the influence of the assumption of non-independent recur-
rence. Additionally, as it is possible that the occurrence of an outbreak could affect subsequent
exposure, we conducted an SCCS analysis including a 3-year pre-exposure period.
As the precise dates of outbreaks and PMVC initiation were not always available, we
assumed, where missing, that outbreaks started in the middle of the year and that exposure to
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PMVCs started at the end of the year. The influence of these assumptions was explored in sen-
sitivity analysis.
Furthermore, to assess how the choice of the study period influenced our results, we also
conducted a sensitivity analysis considering alternative start and end dates: (i) 1 January 2007
to 31 December 2018 and (ii) 1 January 2005 to 31 December 2014.
Lastly, to assess whether spatial autocorrelation could have affected our results, we con-
ducted multiple resampling. In each resampling from the SCCS study sample, we only sampled
1 random province per country and reestimated the IRR of the association between exposure
and the event. This approach implicitly accounts for spatial autocorrelation within, but not
across, countries.
Analysis using the cohort design. We compared the results obtained using the SCCS
method with those obtained using a classical cohort design. The study sample consisted of all
provinces belonging to the 34 African countries at high or moderate risk for yellow fever [3].
We used univariate and multivariate Poisson regression models with robust variance, consid-
ering exposure alternatively as a binary (pre- versus post-PMVC) or continuous (vaccination
coverage) time-dependent variable.
In a cohort design, the choice of covariates to include is critical to prevent bias due to resid-
ual confounding. However, there is currently no clear consensus about the demographic and
environmental drivers of yellow fever. We thus considered 2 (partially overlapping) sets of
covariates (S1 Text). Both sets of variables were documented to reproduce well the presence
and absence of yellow fever records at the province level. The first set of covariates was previ-
ously used in a statistical model, whereas the second was used in a mechanistic model [4,10].
Statistical models aim to describe the patterns of association between species (including infec-
tious agent species) and environmental variables, while mechanistic models aim at explicitly
Table 1. Analysis plan for the measure of the association between yellow fever vaccination activities and outbreak risk.
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representing biological processes in species’ occurrence [25]. The association between each
covariate and exposure status was explored using modified Poisson regression.
Number of outbreaks averted and prevented fraction
For each province i, we estimated the expected number of outbreaks averted by PMVC, Ai,
using the formula
Ai ¼ liðT   diÞð1   IRRÞ ð1Þ
where T is the total time of observation, di is the time at which the PMVC was implemented (if
no PMVC in province i, then di = T), λi is the rate of outbreak occurrence in a Poisson process
in the absence of PMVC, and IRR is the incidence rate ratio after versus before PMVC imple-
mentation. With NE i being the number of outbreaks observed in province i during the pre-









We obtained 95% confidence intervals for A using bootstrap resampling (10,000 samples).
For each sample, a value of IRR was randomly sampled based on the parameters estimated in
the SCCS analysis.
Finally, based on Â and N, the total number of outbreaks observed, we obtained the out-
break prevented fraction, PF, with





Outbreak occurrence and PMVCs
A total of 96 outbreaks out of 97 records (99.0%) were geographically resolved. Among the 479
provinces in 34 countries within the African endemic or at-risk region for yellow fever, 81
provinces (16.9%) in 18 countries experienced at least 1 yellow fever outbreak between 2005
and 2018 (Fig 1A), including 12 provinces experiencing more than 1 outbreak. The Poisson
probability distribution applied satisfactorily to the observed outbreak distribution (S1 Table).
Overall, 124 (25.9%) provinces were targeted for at least 1 PMVC (Fig 1B). The SCCS study
sample consisted of 33 (6.9%) provinces having experienced both outbreak and PMVC imple-
mentation over the study period. Temporal patterns in the estimated population-level vaccina-
tion coverage for this sample are displayed in S1 Fig. The median difference between the post-
and the pre-PMVC estimate of vaccination coverage was 24.2 percentage points (interquartile
range: 9.4–42.7) (S2 Fig).
SCCS analysis
In the SCCS study sample, the first outbreak occurred during the pre-PMVC (unexposed)
period in 26 (78.8%) provinces, and during the post-PMVC (exposed) period in 7 (21.2%)
provinces (Fig 2). Under baseline assumptions, this corresponded to a significantly reduced
IRR of 0.14 (95% CI 0.06–0.34) for the exposed versus unexposed periods. A similar protective
association was observed when considering all outbreaks instead of only the first outbreak
PLOS MEDICINE Impact of mass vaccination campaigns on yellow fever outbreaks
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Fig 1. Occurrence of yellow fever outbreaks and preventive mass vaccination campaigns at the province level over the 2005–2018 period. (A) Yellow fever
outbreaks. (B) Preventive mass vaccination campaigns. Maps were produced using GADM version 2.0.
https://doi.org/10.1371/journal.pmed.1003523.g001
Fig 2. Swimmer plot of the chronology of exposure to preventive mass vaccination campaigns (PMVCs) and yellow fever outbreaks among the 33 African
provinces both affected by an outbreak and targeted for a PMVC (2005–2018). (A) Time distribution of yellow fever outbreaks. (B) Swimmer plot. The 3-letter
codes on the y-axis refer to International Organization for Standardization county codes (see S2 Table for complete province and country names).
https://doi.org/10.1371/journal.pmed.1003523.g002
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(IRR 0.19, 95% CI 0.09–0.39) or when including a 3-year pre-exposure period (IRR 0.14, 95%
CI 0.05–0.40).
Considering estimates of population-level vaccine coverage as a categorical variable allowed
us to observe a reduced risk of outbreak for higher levels of coverage (Table 2). Considering
vaccine coverage as a continuous linear exposure led to a better fit of the model (likelihood
ratio test: p = 0.44). Doing so, we estimated that a 10% increase in vaccine coverage was associ-
ated with a decrease in risk of outbreak of 41% (IRR 0.59, 95% CI 0.46–0.76).
Sensitivity analysis
The negative association between exposure to PMVCs and outbreak remained significant
across a range of assumptions regarding the imputation of the date (within the same year) of
PMVC implementation and outbreak starting date (when missing), and across various obser-
vation periods (S3 and S4 Tables).
When resampling the SCCS study sample 100 times while allowing only 1 sampled province
per country, and after excluding resampling yielding to random 0 in the corresponding con-
tingency table (n = 16 with no outbreak occurring during exposed periods, thus leading to an
Table 2. Association between exposure to preventive mass vaccination campaigns and yellow fever outbreak in African provinces, 2005–2018.
Model Exposure category Number of events IRR� 95% confidence interval
SCCS model 1
(main analysis)
Unexposed (ref.) 26 1.00 —
Exposed 7 0.14 0.06–0.34
SCCS model 2
(all outbreaks)
Unexposed (ref.) 32 1.00 —
Exposed 11 0.19 0.09–0.39
SCCS model 3 Unexposed (ref.) 11 1.00 Ref.
Pre-exposed (3 years) 15 0.99 0.42–2.30
Exposed 7 0.14 0.05–0.40
SCCS model 4 Vc < 0.2 6 0.61 0.11–3.27
0.2� Vc < 0.4 10 2.40 0.61–9.41
0.4� Vc < 0.6 (ref.) 8 1.00 —
0.6� Vc < 0.8 5 0.29 0.06–1.41
0.8� Vc� 1 4 0.05 0.01–0.28
Cohort model 1
(statistical model)
Unexposed (ref.) 74 1.00 —
Exposed 7 0.37 0.15–0.92
Cohort model 2
(statistical model)
Vc < 0.2 19 0.18 0.07–0.50
0.2� Vc < 0.4 40 0.86 0.43–1.73
0.4� Vc < 0.6 (ref.) 13 1.00 —
0.6� Vc < 0.8 5 0.49 0.17–1.40
0.8� Vc� 1 4 0.11 0.03–0.36
Cohort model 3
(mechanistic model)
Unexposed (ref.) 74 1.00 —
Exposed 7 0.65 0.26–1.65
Cohort model 4
(mechanistic model)
Vc < 0.2 19 0.07 0.03–0.18
0.2� Vc < 0.4 40 0.77 0.40–1.48
0.4� Vc < 0.6 (ref.) 13 1.00 —
0.6� Vc < 0.8 5 0.47 0.16–1.40
0.8� Vc� 1 4 0.13 0.04–0.41
�For cohort models, IRR are adjusted on several demographic and environmental covariates, depending of the model (statistical or mechanistic), see S1 Text.
IRR, incidence rate ratio; SCCS, self-controlled case series; Vc, population-level vaccination coverage.
https://doi.org/10.1371/journal.pmed.1003523.t002
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infinite confidence interval surrounding the association measure), we obtained an averaged
IRR of 0.09 (95% CI 0.01–0.62).
Cohort-style analysis
In a cohort design, over the 81 outbreaks (first outbreaks only) that occurred over the study
period, 74 occurred during the unexposed period versus 7 occurring in the exposed period.
Most of the environmental covariates we explored were associated with exposure to PMVCs
(Table B in S1 Text). Exposure to PMVCs was associated with a significant reduced risk of out-
break (IRR 0.37, 95% CI 0.15–0.92) when adjusting for the covariates obtained from a statisti-
cal model. When adjusting for covariates obtained from a mechanistic model, exposure to
PMVC was not significantly associated with the risk of outbreak (IRR 0.65, 95% CI 0.26–1.65)
(detailed results in Table D in S1 Text). For both sets of covariates, we observed an inverse
U-shaped association between the estimates of vaccination coverage and the risk of outbreak,
with the risk decreasing for the lowest and highest values of vaccination coverage (Table 2).
Number of outbreaks averted and prevented fraction
Based on the value of IRR estimated in the main analysis (IRR 0.14, 95% CI 0.06–0.34), we esti-
mated that PMVCs implemented over the study period averted in median 50 (95% CI 28-80)
outbreaks. When considering the 96 outbreaks in total that occurred over the study period,
this corresponds to a prevented fraction of 34% (95% CI 22%-45%).
Discussion
In this paper, using the SCCS method, we quantified the preventive effect of PMVCs on the
risk of yellow fever outbreak at the province level, documenting a 86% (95% CI 66% to 94%)
reduction in the risk of outbreak occurrence for provinces that were targeted by a PMVC. This
result was robust over a range of assumptions. When using an estimate of population-level
coverage as the exposure, we also observed a dose–response preventive effect on the risk of
outbreak. Considering the scale of PMVC implementation during the study period, this corre-
sponded to an estimated 22% to 45% of outbreaks averted by PMVCs in Africa between 2005
and 2018. In the cohort design analysis, the association between PMVCs and outbreak was
sensitive to the choice of adjustment variables. Moreover, we observed a puzzling U-shaped
association between vaccination coverage and the risk of outbreak in the cohort analysis. Over-
all, these results suggest a risk of residual confounding that the SCCS method, but not the
cohort design, could overcome, at least for time-independent confounders. To our knowledge,
this is the first time an SCCS analysis was conducted at the population level.
Considering evidence of yellow fever vaccine efficacy at the individual level, a preventive
effect of PMVCs on outbreak risk was indeed expected. This is why we think that the cohort
analysis results may be biased by residual confounding, whereas we consider the results
obtained from the SCCS method to be more trustworthy. Indeed, the indication of provinces
for PMVCs partly relies on a risk assessment [3]. For the results of the cohort design analysis
to be valid, one needs to account for all possible confounders in the association between
PMVCs and outbreak. This is particularly challenging as the environmental and demographic
drivers of yellow fever circulation are not fully understood yet [9]. Another result suggesting
residual confounding in the cohort design analysis is the U-shaped relationship between vacci-
nation coverage and outbreak risk. The yellow fever vaccine has not been introduced in large
regions of East Africa yet, as the risk of yellow fever is usually considered as low, though exist-
ing (e.g., Kenya). This can yield a spurious negative association between a low level of vaccina-
tion coverage and outbreak risk when confounders are not controlled for. In the SCCS
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analysis, we did observe a linear relationship in the expected association between vaccination
coverage and outbreak risk, providing further evidence of reduced residual confounding as
compared to the cohort analysis. Analyzing cases only, instead of the corresponding complete
cohort, translates into a loss of efficiency, but previous work has shown that this loss is small,
especially when the fraction of the sample experiencing the exposure is high [26]. Moreover,
this loss of efficiency has to be weighed against a better control of time-invariant confounders.
Previous examples have illustrated that the SCCS design is likely to produce more trustworthy
results than the corresponding cohort analysis, especially when a strong indication bias is likely
[27,28].
Although the SCCS method was originally developed to be used at the individual level, we
ensured that our analysis complied with all the method’s requirements [12,15]. Exposure and
outcomes were ascertained independently. The list of PMVCs was compiled based on informa-
tion provided by international funders. Outbreak occurrence data were compiled from WHO
sources, which themselves compile outbreak notification from countries as per the 2005 Inter-
national Health Regulations. The observation period was chosen in order to maximize the
chance that cases experienced the exposure period. Indeed, our observation period started
shortly before the launch of the Yellow Fever Initiative. The Yellow Fever Initiative boosted
the use of PMVCs, which had before that been very rare since the 1960s [4,19]. The choice of
the long and unlimited exposure period was based on evidence regarding the long-lasting pro-
tection conferred by the yellow fever vaccine, and the SCCS method has been previously used
successfully while considering long and unlimited risk periods [29]. The application of the
SCCS design at the population level certainly deserves further methodological assessments to
ensure its robustness to specific issues when transposing it to the population level, especially
those related to overdispersed or autocorrelated events. We hope that the present work will
stimulate further studies characterizing the advantages and drawbacks of SCCS as compared
to more classically used population-level designs, for instance interrupted time series.
Under the assumption of causality, the IRR we estimate represents the average effect for a
province being targeted by a PMVC, which corresponds to the average treatment effect in the
counterfactual framework. This average effect likely masks large heterogeneity in the local
effect of a PMVC. Indeed, PMVCs occur in populations with various baseline levels of immu-
nity, and they may achieve various levels of post-intervention coverage. The dose–response
relationship we observed in the association between vaccination coverage and outbreak risk
brought additional evidence for a causal link between PMVCs and reduced outbreak risk.
When looking at higher values of vaccination coverage, it is notable that several outbreaks
(n = 4) occurred at estimated levels of vaccination coverage> 80%, an empirical threshold that
has been often suggested as protective against outbreaks [30]. While keeping in mind all the
limitations such province-based estimates of vaccination coverage may have (outbreaks could
occur in small pockets with low vaccination coverage even in provinces with high coverage),
these occurrences of outbreaks at estimated vaccination coverage> 80% can be viewed as an
argument to ensure high vaccination coverages homogeneously in at-risk areas, and to sustain
them after PMVCs by ensuring routine infant vaccination.
Relying on our estimate of the preventive effect of PMVCs, the timing of implementation of
these PMVCs, and the number outbreaks observed during the study period, we further esti-
mated that PMVCs have averted 28 to 80 outbreaks in Africa between 2005 and 2018, corre-
sponding to a prevented fraction lying between 22% and 45%. Garske et al. previously
estimated that vaccination campaigns conducted up to 2013 averted between 22% and 31% of
yellow fever cases and deaths in Africa [4], while Shearer et al. estimated that all vaccination
activities (including routine infant vaccination) conducted up to 2016 have averted 33% to
39% of cases [5]. Our estimates were in a comparable range, although direct comparison with
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these model-based estimates is not straightforward. Indeed, the latter are expressed as propor-
tions of all yellow fever cases, including sylvatic cases that are not linked to outbreaks. Prevent-
ing outbreaks of epidemic-prone diseases is critical for ensuring global health security, yet
there are few empirical studies that quantify the impact of public health interventions like
immunization on the risk of outbreaks.
A main limitation of our study is that it does not account for possible time-varying con-
founders. Environmental changes affecting vector-borne diseases have been documented
across tropical Africa over the study period, probably the main one being changing land use
such as deforestation [31,32]. More frequent intrusions of humans into forest and jungles,
together with increasing human mobility between endemic and non-endemic areas, have also
been suggested to have affected yellow fever risk in the recent period [33]. Similarly, recent
international emphasis on yellow fever may have led to better surveillance of the disease in the
recent years. However, these various factors are likely to have increased the risk of outbreaks
and the probability of outbreak detection in the recent period, which overlaps with the post-
PMVC period in our study sample. This may have led to an underestimate of the association
between PMVCs and yellow fever outbreaks. Lastly, historical vaccination activities that
occurred up to the 1970s may potentially act as a time-varying confounder. Indeed, the
contribution of older people (those potentially exposed to these historical campaigns) to the
population-level immunity may decrease over time by population renewal. However, the cor-
responding bias is likely limited, considering the population structure skewed towards younger
individuals in the region considered here. Moreover, such a bias is likely to have led to an
underevaluation of the association between PMVCs and yellow fever outbreaks. Indeed,
decreasing population-level immunity would have increased the risk of outbreak during the
more recent period, which corresponds to the post-PMVC period.
Previous quantifications of the outstanding health impact of vaccination activities have
mainly focused on cases or deaths prevented, and have relied on mathematical models whose
structures and assumptions may be difficult to understand by a non-expert audience, whether
that be decision-makers or targeted populations [34,35]. Here we further document vaccina-
tion impact using an empirical, maybe more intuitive approach, thus allowing for a triangula-
tion of methods to further document the beneficial impact of yellow fever vaccine campaigns.
This method relies on data that are quite easily accessible. Thus, our method could be applied
to other diseases for which PMVCs are implemented, such as polio, meningitis, or cholera. Due
to the COVID-19 pandemic, WHO recommended temporary suspension of preventive cam-
paigns while risk was assessed, and effective measures for reducing COVID-19 circulation were
established. In consequence, regarding yellow fever specifically, 4 countries postponed vaccina-
tion campaigns [36]. Our results provide additional evidence to encourage a rapid rescheduling
of these vaccine campaigns in order to prevent further outbreaks of preventable disease.
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Writing – original draft: Kévin Jean.
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